Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy von Chong, Elise A, Ruella, Marco, Schuster, Stephen J

Volltext

Vaccination With Patient-Specific Tumor-Derived Antigen in First Remission Improves Disease-Free Survival in Follicular Lymphoma von SCHUSTER, Stephen J, NEELAPU, Sattva S, MCGAUGHEY, Dean S, JAFFE, Elaine S, CHONG, Elise A, REYNOLDS, Craig W, BERRY, Donald A, SANTOS, Carlos F, POPA, Mihaela A, MCCORD, Amy M, KWAK, Larry W, GAUSE, Barry L, JANIK, John E, MUGGIA, Franco M, GOCKERMAN, Jon P, WINTER, Jane N, FLOWERS, Christopher R, NIKCEVICH, Daniel A, SOTOMAYOR, Eduardo M

Volltext

Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel von Ghilardi, Guido, Paruzzo, Luca, Patel, Vrutti, Svoboda, Jakub, Chong, Emeline R, Fardella, Eugenio, Chong, Elise A, Gabrielli, Giulia, Nasta, Sunita D, Landsburg, Daniel J, Carter, Jordan, Pajarillo, Raymone, Barta, Stefan K, White, Griffin, Weber, Elizabeth, Napier, Ellen, Porter, David L, Garfall, Alfred L, Schuster, Stephen J, Ruella, Marco

Volltext

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas von Schuster, Stephen J, Svoboda, Jakub, Chong, Elise A, Nasta, Sunita D, Mato, Anthony R, Anak, Özlem, Brogdon, Jennifer L, Pruteanu-Malinici, Iulian, Bhoj, Vijay, Landsburg, Daniel, Wasik, Mariusz, Levine, Bruce L, Lacey, Simon F, Melenhorst, Jan J, Porter, David L, June, Carl H

Volltext

PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR von Chong, Elise A., Melenhorst, J.Joseph, Lacey, Simon F., Ambrose, David E., Gonzalez, Vanessa, Levine, Bruce L., June, Carl H., Schuster, Stephen J.

Volltext

Radiation Therapy for Relapsed or Refractory Diffuse Large B-Cell Lymphoma: What Is the Right Regimen for Palliation? von Wright, Christopher M., Dreyfuss, Alexandra D., Baron, Jonathan A., Maxwell, Russell, Mendes, Amberly, Barsky, Andrew R., Doucette, Abigail, Svoboda, Jakub, Chong, Elise A., Jones, Joshua A., Maity, Amit, Plastaras, John P., Paydar, Ima

Volltext

Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy von Chong, Elise A., Alanio, Cécile, Svoboda, Jakub, Nasta, Sunita D., Landsburg, Daniel J., Lacey, Simon F., Ruella, Marco, Bhattacharyya, Siddharth, Wherry, E. John, Schuster, Stephen J.

Volltext

CAR-T for large B-cell lymphomas: the clock is ticking von Chong, Elise A.

Volltext

CAR‐T TREK through the lymphoma universe, to boldly go where no other therapy has gone before von Ghilardi, Guido, Braendstrup, Peter, Chong, Elise A., Schuster, Stephen J., Svoboda, Jakub, Ruella, Marco

Volltext

No CNS sanctuary for lymphoma from CAR T von Chong, Elise A., Schuster, Stephen J.

Volltext

T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy von Ghilardi, Guido, Fraietta, Joseph A., Gerson, James N., Van Deerlin, Vivianna M., Morrissette, Jennifer J. D., Caponetti, Gabriel C., Paruzzo, Luca, Harris, Jaryse C., Chong, Elise A., Susanibar Adaniya, Sandra P., Svoboda, Jakub, Nasta, Sunita D., Ugwuanyi, Ositadimma H., Landsburg, Daniel J., Fardella, Eugenio, Waxman, Adam J., Chong, Emeline R., Patel, Vrutti, Pajarillo, Raymone, Kulikovskaya, Irina, Lieberman, David B., Cohen, Adam D., Levine, Bruce L., Stadtmauer, Edward A., Frey, Noelle V., Vogl, Dan T., Hexner, Elizabeth O., Barta, Stefan K., Porter, David L., Garfall, Alfred L., Schuster, Stephen J., June, Carl H., Ruella, Marco

Volltext

Salvage radiotherapy for relapsed/refractory non‐Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy von Yegya-Raman, Nikhil, Wright, Christopher M., LaRiviere, Michael J., Baron, Jonathan A., Lee, Daniel Y., Landsburg, Daniel J., Svoboda, Jakub, Nasta, Sunita D., Gerson, James N., Barta, Stefan K., Chong, Elise A., Schuster, Stephen J., Maity, Amit, Facciabene, Andrea, Paydar, Ima, Plastaras, John P.

Volltext

Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy von Smith, Melody, Dai, Anqi, Ghilardi, Guido, Amelsberg, Kimberly V., Devlin, Sean M., Pajarillo, Raymone, Slingerland, John B., Beghi, Silvia, Herrera, Pamela S., Giardina, Paul, Clurman, Annelie, Dwomoh, Emmanuel, Armijo, Gabriel, Gomes, Antonio L. C., Littmann, Eric R., Schluter, Jonas, Fontana, Emily, Taur, Ying, Park, Jae H., Palomba, Maria Lia, Halton, Elizabeth, Ruiz, Josel, Jain, Tania, Pennisi, Martina, Afuye, Aishat Olaide, Perales, Miguel-Angel, Freyer, Craig W., Garfall, Alfred, Gier, Shannon, Nasta, Sunita, Landsburg, Daniel, Gerson, James, Svoboda, Jakub, Cross, Justin, Chong, Elise A., Giralt, Sergio, Gill, Saar I., Riviere, Isabelle, Porter, David L., Schuster, Stephen J., Sadelain, Michel, Frey, Noelle, Brentjens, Renier J., June, Carl H., Pamer, Eric G., Peled, Jonathan U., Facciabene, Andrea, van den Brink, Marcel R. M., Ruella, Marco

Volltext

BTK Inhibitors in Cancer Patients with COVID-19: "The Winner Will be the One Who Controls That Chaos" (Napoleon Bonaparte) von Chong, Elise A., Roeker, Lindsey E., Shadman, Mazyar, Davids, Matthew S., Schuster, Stephen J., Mato, Anthony R.

Volltext

Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma von Wright, Christopher M., LaRiviere, Michael J., Baron, Jonathan A., Uche, Chibueze, Xiao, Ying, Arscott, W. Tristram, Anstadt, Emily J., Barsky, Andrew R., Miller, David, LaRose, Meredith I., Landsburg, Daniel J., Svoboda, Jakub, Nasta, Sunita D., Gerson, James N., Barta, Stefan K., Chong, Elise A., Schuster, Stephen J., Paydar, Ima, Maity, Amit, Plastaras, John P.

Volltext

Front‐line, dose‐escalated immunochemotherapy is associated with a significant progression‐free survival advantage in patients with double‐hit lymphomas: a systematic review and me... von Howlett, Christina, Snedecor, Sonya J., Landsburg, Daniel J., Svoboda, Jakub, Chong, Elise A., Schuster, Stephen J., Nasta, Sunita Dwivedy, Feldman, Tatyana, Rago, Allison, Walsh, Kristy M., Weber, Scott, Goy, Andre, Mato, Anthony

Volltext

Don't Get Stuck on the Shoulder: Radiation Oncologists Should Get Into the CAR With T-Cell Therapies von Plastaras, John P., Chong, Elise A., Schuster, Stephen J.

Volltext

Immunotherapy with cells von Chong, Elise A., Porter, David L.

Volltext

Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer von Lee, Yong Gu, Guruprasad, Puneeth, Ghilardi, Guido, Pajarillo, Raymone, Sauter, Christopher Tor, Patel, Ruchi, Ballard, Hatcher J, Hong, Seok Jae, Chun, Inkook, Yang, Nicholas, Amelsberg, Kimberly V, Cummins, Katherine D, Svoboda, Jakub, Gill, Saar, Chong, Elise A, North, Khrystyna, Church, Sarah E, Fraietta, Joseph A, Chang, Wan-Jung, Lacey, Simon F, Lu, Xueqing Maggie, Zhang, Yunlin, Whig, Kanupriya, Schultz, David C, Cherry, Sara, Gerson, James, Schuster, Stephen J, Porazzi, Patrizia, Ruella, Marco

Volltext

CAR T cell viability release testing and clinical outcomes: is there a lower limit? von Chong, Elise A., Levine, Bruce L., Grupp, Stephan A., Davis, Megan M., Siegel, Don L., Maude, Shannon L., Gladney, Whitney L., Frey, Noelle V., Porter, David L., Hwang, Wei-Ting, Chong, Emeline R., June, Carl H., Schuster, Stephen J.

Volltext